Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 92Lung Neoplasms 32NSCLC 7Brain Neoplasms 7Meningeal Carcinomatosis 4Neoplasm Metastasis 3Carcinoma, Squamous Cell 2Bronchial Neoplasms 2Adenocarcinoma of Lung 2Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1Resectable Non-small Cell Lung Cancer 1Rare Tumour 1Prostatic Neoplasms 1Progression Free Survival 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Carcinoma 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Non-Small Cell Lung Cancer With EGFR T790M Mutation 1Non-Small Cell Lung Cancer With EGFR Mutation 1Non Small Cell Lung Cancer Metastatic 1Neurocognitive 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Lung Cancer Metastatic 1Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1Glioblastoma 1Eunuchism 1Erectile Dysfunction 1

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × osimertinib × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡